v3.26.1
Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
$ in Thousands
Jun. 30, 2026
Dec. 31, 2025
Current assets:    
Cash $ 6,663 $ 9,345
Trade accounts receivable, net of allowance for expected credit losses of $462 and $457, respectively 34,770 33,948
Inventories, net 58,745 54,008
Prepaid expenses and other current assets 6,980 8,500
Total current assets 107,158 105,801
Property, plant and equipment, net 39,514 40,397
Goodwill 45,369 45,376
Other intangible assets, net 10,386 10,933
Deferred income taxes, net 10,335 10,494
Other noncurrent assets 3,395 3,911
Total assets 216,157 216,912
Current liabilities:    
Accounts payable 22,601 17,423
Current portion of long-term debt 1,750 4,125
Accrued compensation and related benefits 2,930 2,754
Accrued expenses and other current liabilities 10,074 13,031
Total current liabilities 37,355 37,333
Long-term debt, net 42,854 45,526
Deferred income taxes 934 1,000
Other noncurrent liabilities 2,413 2,919
Total liabilities 83,556 86,778
Commitments and Contingencies  
Stockholders’ equity:    
Preferred stock – par value $.10 per share; authorized 1,000,000 shares; none issued 0 0
Common stock – par value $.10 per share; authorized 40,000,000 shares; issued – 21,099,383 shares at June 30, 2026 and 21,092,617 shares at December 31, 2025; outstanding – 16,663,269 shares at June 30, 2026 and 16,656,503 shares at December 31, 2025 2,110 2,109
Capital in excess of par value 192,983 192,859
Accumulated deficit (38,248) (40,340)
Accumulated other comprehensive loss (2,846) (3,141)
Treasury stock - at cost; 4,436,114 shares at June 30, 2026 and 4,436,114 shares at December 31, 2025 (21,492) (21,492)
Total Ultralife Corporation equity 132,507 129,995
Non-controlling interest 94 139
Total stockholders’ equity 132,601 130,134
Total liabilities and stockholders’ equity $ 216,157 $ 216,912